A systematic review of the efficacy and tolerability of hydroxyethylrutosides for improvement of the signs and symptoms of chronic venous insufficiency

Journal of Clinical Pharmacy and Therapeutics

Volumn 40, Issue 2, 2015, Pages 177-185

  Aziz, Z ^a   Tang, W L ^a   Chong, N J ^a   Tho, L Y ^a  

^a UNIVERSITY OF MALAYA   (Malaysia)

Author keywords

chronic venous insufficiency; flavonoids; hydroxyethylrutosides; meta analysis; oedema; pain

Indexed keywords

MONOXERUTIN; PLACEBO; RUTOSIDE; TROXERUTIN;

ABDOMINAL PAIN; CHRONIC VEIN INSUFFICIENCY; CINAHL; COCHRANE LIBRARY; COMPRESSION BANDAGE; DIARRHEA; DRUG EFFICACY; DRUG TOLERABILITY; EDEMA; EMBASE; EPISTAXIS; FLATULENCE; HUMAN; LEG PAIN; MEDLINE; META ANALYSIS; MUSCLE CRAMP; NAUSEA; PARESTHESIA; PRURITUS; RANDOMIZED CONTROLLED TRIAL (TOPIC); RESTLESS LEGS SYNDROME; REVIEW; SWELLING; SYSTEMATIC REVIEW; ULCER; ANALOGS AND DERIVATIVES; CHRONIC DISEASE; PHYTOTHERAPY; VENOUS INSUFFICIENCY;

CHRONIC DISEASE; HUMANS; HYDROXYETHYLRUTOSIDE; PHYTOTHERAPY; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RUTIN; VENOUS INSUFFICIENCY;

EID: 84924159934     PISSN: 02694727     EISSN: 13652710     Source Type: Journal    
DOI: 10.1111/jcpt.12247     Document Type: Review

References (41)

1. Nicolaides AN,. Investigation of chronic venous insufficiency: a consensus statement (France, March 5-9, 1997). Circulation, 2000; 102: E126-E163.
2. Kurz X, Kahn SR, Abenhaim L, et al,. Chronic venous disorders of the leg: epidemiology, outcomes, diagnosis and management. Summary of an evidence-based report of the VEINES task force. Venous insufficiency epidemiologic and economic studies. Int Angiol, 1999; 18: 83-102.
3. Kaplan RM, Criqui MH, Denenberg JO, et al,. Quality of life in patients with chronic venous disease: San Diego population study. J Vasc Surg, 2003; 37: 1047-1053.
4. Milic DJ,. Prevalence and socioeconomic data in chronic venous disease: how useful are they in planning appropriate management. Medicographia, 2011; 33: 253-258.
5. Partsch H,. Compression therapy of the legs, a review. J Dermatol Surg Oncol, 1991; 17: 799-805.
6. Eberhardt RT, Raffetto JD,. Chronic venous insufficiency. Circulation, 2005; 111: 2398-2409.
7. Cheatle TR, Scurr JH, Smith PDC,. Drug treatment of chronic venous insufficiency and venous ulceration: a systematic review. J R Soc Med, 1991; 84: 354-358.
8. Wadworth AN, Faulds D,. Hydroxyethylrutosides. A review of its pharmacology, and therapeutic efficacy in venous insufficiency and related disorders. Drugs, 1992; 44: 1013-1032.
9. Firuzi O, Miri R, Tavakkoli M, et al,. Antioxidant therapy: current status and future prospects. Curr Med Chem, 2011; 18: 3871-3888.
10. Zuccarelli F, Taccoen A, Coget JM, et al,. Treatment of venous ulcers with Troxerutin: a randomised double-blind, controlled study. Int Angiol, 1996; 15: 53.
11. Ramelet AA, Boisseau MR, Allegra C, et al,. Veno-active drugs in the management of chronic venous disease. An international consensus statement: current medical position, prospective views and final resolution. Clin Hemorheol Microcirc, 2005; 33: 309-319.
12. Gohel MS, Davies AH,. Pharmacological agents in the treatment of venous disease: an update of the available evidence. Curr Vasc Pharmacol, 2009; 7: 303-308.
13. Roland IH, Bougelet C, Ninane N, et al,. Effect of hydroxyethylrutosides on hypoxia-induced neutrophil adherence to umbilical vein endothelium. Cardiovasc Drugs Ther, 1998; 12: 375-381.
14. Jassens D, Michiels C, Arnould T, et al,. Effects of hydroxyethylrutosides on hypoxia-induced activation of human endothelial cells in vitro. Br J Pharmacol, 1996; 118: 599-604.
15. Oxerutins. Mechanisms of action. 2002. Available at http://therapy.epnet.com/nat/GetContent.asp?siteid=EBSCO&chunkiid=24447#common (accessed 26 November 2014).
16. Schoonees A, Visser J, Musekiwa A, et al,. Pycnogenol® (extract of French maritime pine bark) for the treatment of chronic disorders. Cochrane Database Syst Rev, 2012; 4: CD008294.
17. Poynard T, Valterio C,. Meta-analysis of hydroxyethylrutosides in the treatment of chronic venous insufficiency. Vasa, 1994; 23: 244.
18. Martinez-Zapata MJ, Bonfill Cosp X, Moreno RM, et al,. Phlebotonics for venous insufficiency. Cochrane Database Syst Rev, 2008; 3: CD003229.
19. Scallon C, Bell-Syer SEM, Aziz Z,. Flavonoids for treating venous leg ulcers. Cochrane Database Syst Rev, 2013; 5: CD006477.
20. Higgins JPT, Green S, (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.2 [updated September 2009]. The Cochrane Collaboration, 2009. Available at http://handbook.cochrane.org/ (accessed on 17 July 2013). doi: 10.1002/9780470712184.
21. Belcaro G, Rulo A, Candiani C,. Evaluation of the microcirculatory effects of Venoruton (HR) in patients with chronic venous hypertension by Laser-Doppler flowmetry, transcutaneous PO2 and PCO2 measurements, leg volumetry and ambulatory venous pressure measurements. Phlebology, 1989; 1989: 23-29.
22. Cesarone MR, Incandela L, Desanctis MT, et al,. Treatment of edema and increased capillary filtration in venous hypertension with HR (Paroven, Venoruton; 0-(β-hydroxyethyl)-rutosides): a clinical, prospective, placebo-controlled, randomized, dose-ranging trial. J Cardiovasc Pharmacol Ther, 2002; 7: S21-S24.
23. Cloarec M, Clement R, Griton P,. A double-blind clinical trial of hydroxyethylrutosides in the treatment of the symptoms and signs of chronic venous insufficiency. Phlebology, 1996; 11: 76-82.
24. Incandela L, Belcaro G, Renton S, et al,. HR (Paroven, Venoruton; 0-(β-hydroxyethyl)-rutosides) in venous hypertensive microangiopathy: a prospective, placebo-controlled, randomized trial. J Cardiovasc Pharmacol Ther, 2002; 7: S7-S10.
25. Neumann HAM, van den Broek MJTB,. Evaluation of O-(β-hydroxyethyl)-rutosides in chronic venous insufficiency by means of non-invasive techniques. Phlebology, 1990; 5: 13-20.
26. Nocker W, Diebschlag W, Lehmacher W,. Clinical trials of the dose related effects of 0-(b-hydroxyethyl)-rutosides in patients with chronic venous insufficiency. Phlebology, 1990; 5: 23-26.
27. Pedersen FM, Hamberg O, Sørensen MD, et al,. Effect of 0-(beta-hydroxyethyl)-rutoside (Venoruton) on symptomatic venous insufficiency in the lower limbs. Ugesk Laeger, 1992; 154: 2561.
28. Petruzzellis V, Troccoli T, Candiani C, et al,. Oxerutins (Venoruton®): efficacy in chronic venous insufficiency: a double-blind, randomized, controlled study. Angiology, 2002; 53: 257-263.
29. Pulvertaft TB,. General practice treatment of symptoms of venous insufficiency with oxerutins. Results of a 660 patient multicentre study in the UK. Vasa, 1983; 12: 373-376.
30. Serralde CF, Aceves AQ,. Clinical trial of the O-(ß-hydroxyethyl)-rutosids) in patients with chronic venous insufficiency [Ensayo clínico de o-(beta-hidroxietil-rutõsidos) en pacientes con insuficiencia venosa crõnica]. Revista Médicadel Hospital General de México, 1990; 53: 102-106.
31. Schultz-Ehrenburg U, Muller B,. Two multicentre clinical trials of two different dosages of O-(B-Hydroxyethyl)-Rutosides in the treatment of leg ulcers. Phlebology, 1993; 8 (Suppl 1): 29-30.
32. Schultz-Ehrenburg U, Muller B,. Two multicentre clinical trials of two different dosages of O-(B-Hydroxyethyl)-Rutosides in the treatment of leg ulcers. Phlebology, 1993; 8 (Suppl 1.1): 29-30.
33. Stegmann WAE, Deichmann B, Hubner K, et al,. Therapeutic benefit of hydroxyethylrutosides (HR) in venous ulcer treatment. A controlled multicentre study. Phlebology, 1986; 1: 617-620.
34. Welch W, Moriau M, van Gysel JP,. A double-blind, placebo controlled trial of o-(beta-hydroxyethyl)-rutosides in patients with chronic venous insufficiency. Novartis, 1985 (Unpublished report).
35. Eklof B, Rutherford RB, Bergan JJ, et al,. Revision of the CEAP classification of chronic venous disorders: a consensus statement. J Vasc Surg, 2004; 40: 1248-1252.
36. Schulz KF,. Assessing allocation concealment and blinding in randomised controlled trials: why bother? Evid Based Ment Health, 2000; 3: 4-5.
37. Suarez-Almazor ME, Belseck E, Homik J, et al,. Identifying clinical trials in the medical literature with electronic databases: MEDLINE alone is not enough. Control Clin Trials, 2000; 21: 476-487.
38. Littlewood C, Ashton J, Chance-Larsen K, et al,. The quality of reporting might not reflect the quality of the study: implications for undertaking and appraising a systematic review. J Man Manip Ther, 2012; 20: 130-134.
39. Rabe E, Pannier F,. Clinical, aetiological, anatomical and pathological classification (CEAP): gold standard and limits. Phlebology., 2012; 27 (Suppl 1): 114-118.
40. Widmer LK, Stathelin HB, Nissen C, A. Sd. Venen-, Arterien-, Krankheiten, koronaire Herzkrankhei bei berufstatigen. Bern: Verlag Hans Huber, 66-82, 1981.
41. Moher D, Hopewell S, Schulz KF, et al,. CONSORT 2010 Explanation and elaboration: updated guidelines for reporting parallel group randomised trials. J Clin Epidemiol, 2010; 63: e1-e37.